The Charnolosome as a Novel Nanothereranostic Biomarker
eBook - ePub

The Charnolosome as a Novel Nanothereranostic Biomarker

Overcoming Future Challenges in Medicine

  1. 500 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

The Charnolosome as a Novel Nanothereranostic Biomarker

Overcoming Future Challenges in Medicine

About this book

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author's original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases.The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions. - Shares the latest knowledge on the charnolosome and charnolosome-derived nano-vesicles and their significance at a cellular and molecular level - Considers the charnolosome in relation to a range of conditions, including neurodegenerative, metabolic, and multi-drug resistant systemic diseases - Presents future perspectives of the charnolosome in personalized nanotheranostics

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access The Charnolosome as a Novel Nanothereranostic Biomarker by Sushil Sharma in PDF and/or ePUB format, as well as other popular books in Biological Sciences & Molecular Biology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
Academic Press
Year
2024
eBook ISBN
9780443217531
Edition
0
Topic
Biological Sciences
Subtopic
Molecular Biology
Index
Biological Sciences

Table of contents

  1. The Charnolosome as a Novel Nanothereranostic Biomarker
  2. Chapter 1 Transcriptional regulation of charnolosome through gene/base editing
  3. Chapter 2 Charnolosome destabilization induces inflammasome activation
  4. Chapter 3 Charnolosome in charnoly body molecular pathogenesis of gene-manipulated cells and animals
  5. Chapter 4 Charnolosome and inflammasome in chronic MDR diseases
  6. Chapter 5 Charnolosome stabilization inhibits inflammasome activation to confer personalized nanotheranostics benefit in chronic MDR diseases
  7. Chapter 6 Endogenous, natural, and synthetic antioxidants stabilize charnolosome and its exocytosis to confer theranostic benefit by inflammasome inhibition
  8. Chapter 7 Charnolosome stability index (stabilized charnolosome vs. activated inflammasome) determines normal cellular function to remain healthy
  9. Chapter 8 Charnolosome stability index regulates Charnoly body molecular pathogenesis
  10. Chapter 9 Nanotheranostic significance of antioxidants in charnolosome detoxification
  11. Chapter 10 Theranostic significance of charnolosome in personalized nanomedicine
  12. Chapter 11 Environmental toxins and transcriptional regulation of charnolosome
  13. Chapter 12 Antioxidants-mediated charnolosome transcriptional regulation in health and disease
  14. Chapter 13 Mitochondrial bioenergetics, charnolosome, and theranostic potential of antioxidants
  15. Chapter 14 Cellular, molecular, and genetic significance of metallothioneins as charnolosome modulators
  16. Chapter 15 Pharmacogenomics of metallothioneins and other endogenous, natural, and synthetic antioxidants as charnolosome regulators in health and disease
  17. Chapter 16 Environmental pollution and metal ion speciation of metallothioneins
  18. Chapter 17 Metallothioneins as potential charnolopharmacotherapeutics
  19. Chapter 18 Antioxidants as charnolosome stabilizers, charnolophagy enhancers, and intracellular detoxifiers
  20. Chapter 19 Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis, and ferroptosis in chronic MDR diseases in aging
  21. Chapter 20 Charnolosome as a theranostic biomarker in cell therapy and nanomedicine
  22. Chapter 21 Charnolosome nanotheranostics in malnutrition
  23. Chapter 22 Charnolosome nanotheranostics in stress
  24. Chapter 23 Charnolosome nanotheranostics in inflammation
  25. Chapter 24 Charnolosome nanotheranostics in microbial infection
  26. Chapter 25 Charnolosome nanotheranostics in ionizing radiation injuries
  27. Chapter 26 Charnolosome nanotheranostics in congenital diseases
  28. Chapter 27 Charnolosome nanotheranostics in metabolic diseases
  29. Chapter 28 Charnolosome nanotheranostics in hyperlipidemia
  30. Chapter 29 Charnolosome nanotheranostics in obesity
  31. Chapter 30 Charnolosome nanotheranostics in diabetes
  32. Chapter 31 Charnolosome in hepatic diseases
  33. Chapter 32 Charnolosome in GIT diseases
  34. Chapter 33 Charnolosome nanotheranostics in skin diseases
  35. Chapter 34 Charnolosome in musculoskeletal diseases
  36. Chapter 35 Charnolosome nanotheranostics in pulmonary diseases
  37. Chapter 36 Charnolosome nanotheranostics in cardiovascular diseases
  38. Chapter 37 Charnolosome nanotheranostics in renal disease
  39. Chapter 38 Charnolosome nanotheranostics in reproductive system
  40. Chapter 39 Charnolosome nanotheranostics in polysubstance abuse
  41. Chapter 40 Charnolosome nanotheranostics in neuropsychiatric diseases
  42. Chapter 41 Charnolosome nanotheranostics in neurodegenerative diseases
  43. Chapter 42 Charnolosome nanotheranostics in neurodegenerative synucleinopathies
  44. Chapter 43 Charnolosome in Parkinson's disease
  45. Chapter 44 Charnolosome nanotheranostics in Alzheimer disease and other taupathies
  46. Chapter 45 Charnolosome nanotheranostics in acute ischemic stroke and traumatic brain injury
  47. Chapter 46 Attenuation of charnolosome-mediated neurodegenerative α-synucleinopathies by antioxidants
  48. Chapter 47 Charnolosome as a novel nanotheranostic biomarker of aging
  49. Chapter 48 Charnolosome nanotheranostics in inflammatory diseases
  50. Chapter 49 Charnolosome nanotheranostics in autoimmune diseases
  51. Chapter 50 Charnolosome nanotheranostics in cancer (with special reference to multidrug-resistant malignancies)
  52. Chapter 51 Charnolosome nanotheranostics in infectious diseases (With Special Reference to COVID-19 infection)
  53. Chapter 52 Charnolosome nanotheranostics in Mitochondrial Nanomedicine
  54. Chapter 53 Charnolosome-based disease-specific nanotherapeutics
  55. Chapter 54 Physiological, biochemical, pharmacological, and genetic manipulations of charnolosome in personalized nanotheranostics of chronic MDR diseases
  56. Chapter 55 Transcriptional and translational regulation of charnolosome in multidrug-resistant malignancies and other chronic diseases
  57. Chapter 56 Future prospects of charnolosome in evidence-based personalized nanotheranostics
  58. Index